Evidence map›Paper›PMID 34653592›Full record

ArticleJournal of hepatology2022

Global impact of the first wave of COVID-19 on liver transplant centers: A multi-society survey (EASL-ESOT/ELITA-ILTS).

Francesco Paolo Russo, Manhal Izzy, Ashwin Rammohan, Varvara A Kirchner, Tommaso Di Maira, Luca Saverio Belli, Thomas Berg, Marina Carmen Berenguer, Wojciech Grzegorz Polak

Open access · bronzeAbstract readMulticenter Study
In one paragraph

Article in Journal of hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Sars-Cov-2 vaccination in liver transplant recipients: The 'holy grail' in a hostile environment.Liver international : official journal of the International Association for the Study of the Liver · 2022
    Article
  10. COVID-19 and liver disease: where are we now?Nature reviews. Gastroenterology & hepatology · 2022
    Article
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 6 countries.

Francesco Paolo RussoDepartment of Surgery, Oncology and Gastroenterology, University Hospital Padua, Padua Italy. Electronic address: francescopaolo.russo@unipd.it.
Manhal IzzyDepartment of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Ashwin RammohanThe Institute of Liver Disease & Transplantation, Dr. Rela Institute & Medical Centre, Bharath Institute of Higher Education and Research, Chennai, Tamil Nadu, India.
Varvara A KirchnerDepartment of Surgery, University of Minnesota School of Medicine, Minneapolis, Minnesota, USA.
Tommaso Di MairaLiver Transplantation and Hepatology Unit, Hospital Universitari I Politècnic La Fe, Valencia, Spain; CIBERehd, Instituto de Salud Carlos III, Madrid, Spain; ISS La Fe, Valencia, Spain.
Luca Saverio BelliDepartment of Hepatology and Gastroenterology, Niguarda Hospital, Milan, Italy.
Thomas BergDivision of Hepatology, Department of Medicine II, Leipzig University, Medical Center, 04103 Leipzig, Germany.
Marina Carmen BerenguerLiver Transplantation and Hepatology Unit, Hospital Universitari I Politècnic La Fe, Valencia, Spain; CIBERehd, Instituto de Salud Carlos III, Madrid, Spain; ISS La Fe, Valencia, Spain.
Wojciech Grzegorz PolakDepartment of Surgery, Division of HPB and Transplant Surgery, Erasmus MC Transplant Institute, University Medical Centre, Rotterdam, the Netherlands.
Instituto de Salud Carlos III · ESAzienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda · ITBharath University · INErasmus MC Cancer Institute · NLLeipzig University · DEUniversity of Minnesota · USUniversity of Padua · ITVanderbilt University Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsThe global impact of SARS-CoV-2 on liver transplantation (LT) practices across the world is unknown. The goal of this survey was to assess the impact of the pandemic on global LT practices.

methodA prospective web-based survey (available online from 7

resultsOf the 470 transplant centers reached, 128 answered each part of the survey, 29 centers (23%), 64 centers (50%), and 35 centers (27%) from R1, R2, and R3, respectively. When we compared the practices during the first 6 months of the pandemic in 2020 with those a year earlier in 2019, statistically significant differences were found in the number of patients added to the waiting list (WL), WL mortality, and the number of LTs performed. At the regional level, we found that in R2 the number of LTs was significantly higher in 2019 (p <0.01), while R3 had more patients listed, higher WL mortality, and more LTs performed before the pandemic. Countries severely affected by the pandemic ("hit" countries) had a lower number of WL patients (p = 0.009) and LTs (p = 0.002) during the pandemic. Interestingly, WL mortality was still higher in the "non-hit" countries in 2020 compared to 2019 (p = 0.022).

conclusionThe first wave of the pandemic differentially impacted LT practices across the world, especially with detrimental effects on the "hit" countries. Modifications to the policies of recipient and donor selection, organ retrieval, and postoperative recipient management were adopted at a regional or national level. LAY SUMMARY: The health emergency caused by the coronavirus pandemic has dramatically changed clinical practice during the pandemic. The first wave of the pandemic impacted liver transplantation differently across the world, with particularly detrimental effects on the countries badly hit by the virus. The resilience of the entire transplant network has enabled continued organ donation and transplantation, ultimately improving the lives of patients with end-stage liver disease.

Indexed as

Liver TransplantationSARS-CoV-2COVID-19Cross-Sectional StudiesGlobal HealthHumansImmunosuppression TherapyLiving DonorsProspective StudiesTelemedicineTissue and Organ ProcurementWaiting ListsCOVIDLiver TransplantationpandemicSars-Cov-2survey

Identifiers

PMID34653592
PMCPMC8511875
OpenAlexW3205656601

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.